The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Horwitz, StevenO'Connor, Owen A.Pro, BarbaraTrümper, LorenzIyer, SwaminathanAdvani, RanjanaBartlett, Nancy L.Christensen, Jacob HaaberMorschhauser, FranckDomingo-Domenech, EvaRossi, GiuseppeKim, Won-SeokFeldman, TatyanaMenne, T.Belada, DavidIllés, ÁrpádTobinai, KenseiTsukasaki, KunihiroYeh, Su-PengShustov, AndreiHüttmann, AndreasSavage, Kerry J.Yuen, SamZinzani, Pier LuigiMiao, HarryBunn, V.Fenton, KeenanFanale, MichellePuhlmann, M.Illidge, Tim2024-04-252024-04-252022Annals Of Oncology. -33 : 3 (2022), p. 288-298. -Ann. Oncol. - 0923-7534. - 1569-80410923-75341569-8041https://hdl.handle.net/2437/369288The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomafolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM120740OrvostudományokKlinikai orvostudományokhttps://linkinghub.elsevier.com/retrieve/pii/S0923753421048754szerzőhttp://dx.doi.org/10.1016/j.annonc.2021.12.0022024-04-2500075565950000885122922204